MedTrace Logo

PDL-1 Targeting in Resectable Oesophageal Cancer

NCT03087864 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-05-11

No results posted yet for this study

Summary

Objectives The primary objective of this study is to assess the feasibility of preoperative treatment with atezolizumab combined with preoperative chemoradiation (carboplatin, paclitaxel and radiation) in terms of completion of treatment with atezolizumab.

Conditions

  • Esophageal Cancer, Stage II
  • Esophageal Cancer Stage III

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg i.v. day 1-22-43-64-85

DRUG

Carboplatin

Chemotherapy

DRUG

Paclitaxel

Chemotherapy

RADIATION

Radiotherapy 23 x 1.8 Gy

Radiotherapy

Sponsors & Collaborators

  • UMC Utrecht

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Hanneke WM van Laarhoven, Prof. dr. · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-28
Primary Completion
2019-07-01
Completion
2019-07-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03087864 on ClinicalTrials.gov